Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 252

1.

Monocyte deactivation in septic shock.

Heumann D, Glauser MP, Calandra T.

Curr Opin Infect Dis. 1998 Jun;11(3):279-83.

PMID:
17033392
2.

Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients.

Viscoli C, Cometta A, Kern WV, Bock R, Paesmans M, Crokaert F, Glauser MP, Calandra T; International Antimicrobial Therapy Group of the European Organization for Research and Treatment of Cancer.

Clin Microbiol Infect. 2006 Mar;12(3):212-6.

3.

Invasive candidiasis: comparison of management choices by infectious disease and critical care specialists.

Eggimann P, Calandra T, Fluckiger U, Bille J, Garbino J, Glauser MP, Marchetti O, Ruef C, Täuber M, Pittet D; Fungal Infection Network of Switzerland.

Intensive Care Med. 2005 Nov;31(11):1514-21. Epub 2005 Sep 20.

PMID:
16172844
4.

Managing serious infections in the hospital: a new model.

Baughman RP, Glauser MP.

Clin Microbiol Infect. 2005 Oct;11 Suppl 5:1-3. No abstract available.

5.

Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000.

Marchetti O, Bille J, Fluckiger U, Eggimann P, Ruef C, Garbino J, Calandra T, Glauser MP, Täuber MG, Pittet D; Fungal Infection Network of Switzerland.

Clin Infect Dis. 2004 Feb 1;38(3):311-20. Epub 2004 Jan 14.

6.

Efficacy of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococci.

Entenza JM, Vouillamoz J, Glauser MP, Moreillon P.

Antimicrob Agents Chemother. 2004 Jan;48(1):86-92.

7.

Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study.

Zanetti G, Bally F, Greub G, Garbino J, Kinge T, Lew D, Romand JA, Bille J, Aymon D, Stratchounski L, Krawczyk L, Rubinstein E, Schaller MD, Chiolero R, Glauser MP, Cometta A; Cefepime Study Group,.

Antimicrob Agents Chemother. 2003 Nov;47(11):3442-7.

8.

Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy.

Cometta A, Kern WV, De Bock R, Paesmans M, Vandenbergh M, Crokaert F, Engelhard D, Marchetti O, Akan H, Skoutelis A, Korten V, Vandercam M, Gaya H, Padmos A, Klastersky J, Zinner S, Glauser MP, Calandra T, Viscoli C; International Antimicrobial Therapy Group of the European Organization for Research Treatment of Cancer.

Clin Infect Dis. 2003 Aug 1;37(3):382-9. Epub 2003 Jul 22.

PMID:
12884163
10.

Fungicidal synergism of fluconazole and cyclosporine in Candida albicans is not dependent on multidrug efflux transporters encoded by the CDR1, CDR2, CaMDR1, and FLU1 genes.

Marchetti O, Moreillon P, Entenza JM, Vouillamoz J, Glauser MP, Bille J, Sanglard D.

Antimicrob Agents Chemother. 2003 May;47(5):1565-70.

11.

Pitfalls in cefepime titration from human plasma: plasma- and temperature-related drug degradation in vitro.

Bugnon D, Giannoni E, Majcherczyk P, Glauser MP, Moreillon P.

Antimicrob Agents Chemother. 2002 Nov;46(11):3654-6.

13.

Single-step extraction of fluconazole from plasma by ultra-filtration for the measurement of its free concentration by high performance liquid chromatography.

Majcherczyk PA, Moreillon P, Decosterd LA, Sanglard D, Bille J, Glauser MP, Marchetti O.

J Pharm Biomed Anal. 2002 May 15;28(3-4):645-51.

PMID:
12008144
14.

Clinafloxacin monotherapy (CI-960) versus ceftazidime plus amikacin for empirical treatment of febrile neutropenic cancer patients.

Glauser MP, Brennscheidt U, Cornely O, Grigg A, Figuera A, Keyserling C, Trostmann U, Welling L, Tack K.

Clin Microbiol Infect. 2002 Jan;8(1):14-25.

15.

MIF regulates innate immune responses through modulation of Toll-like receptor 4.

Roger T, David J, Glauser MP, Calandra T.

Nature. 2001 Dec 20-27;414(6866):920-4.

PMID:
11780066
16.
17.

BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis.

Entenza JM, Hohl P, Heinze-Krauss I, Glauser MP, Moreillon P.

Antimicrob Agents Chemother. 2002 Jan;46(1):171-7.

19.

Critical role of lipopolysaccharide-binding protein and CD14 in immune responses against gram-negative bacteria.

Le Roy D, Di Padova F, Adachi Y, Glauser MP, Calandra T, Heumann D.

J Immunol. 2001 Sep 1;167(5):2759-65.

20.

Macrophage migration inhibitory factor and innate immune responses to bacterial infections.

Froidevaux C, Roger T, Martin C, Glauser MP, Calandra T.

Crit Care Med. 2001 Jul;29(7 Suppl):S13-5. Review.

PMID:
11445727
21.

Antibiotics in sepsis.

Bochud PY, Glauser MP, Calandra T; International Sepsis Forum.

Intensive Care Med. 2001;27 Suppl 1:S33-48. Review. No abstract available.

PMID:
11307369
22.

CD14 expression on monocytes and TNF alpha production in patients with septic shock, cardiogenic shock or bacterial pneumonia.

de Werra I, Zanetti G, Jaccard C, Chioléro R, Schaller MD, Yersin B, Glauser MP, Calandra T, Heumann D.

Swiss Med Wkly. 2001 Jan 27;131(3-4):35-40.

23.

Sensitive bioassay for determination of fluconazole concentrations in plasma using a Candida albicans mutant hypersusceptible to azoles.

Marchetti O, Majcherczyk PA, Glauser MP, Bille J, Moreillon P, Sanglard D.

Antimicrob Agents Chemother. 2001 Mar;45(3):696-700.

24.

Study of Staphylococcus aureus pathogenic genes by transfer and expression in the less virulent organism Streptococcus gordonii.

Stutzmann Meier P, Entenza JM, Vaudaux P, Francioli P, Glauser MP, Moreillon P.

Infect Immun. 2001 Feb;69(2):657-64.

25.

[Evaluation of antibiotic prophylaxis in neutropenic patients with hematologic malignancies].

Delarive P, Baumgartner JD, Glauser MP, Cometta A.

Schweiz Med Wochenschr. 2000 Dec 2;130(48):1837-44. French.

PMID:
11132527
26.

Role of plasma, lipopolysaccharide-binding protein, and CD14 in response of mouse peritoneal exudate macrophages to endotoxin.

Heumann D, Adachi Y, Le Roy D, Ohno N, Yadomae T, Glauser MP, Calandra T.

Infect Immun. 2001 Jan;69(1):378-85.

27.

Fluconazole plus cyclosporine: a fungicidal combination effective against experimental endocarditis due to Candida albicans.

Marchetti O, Entenza JM, Sanglard D, Bille J, Glauser MP, Moreillon P.

Antimicrob Agents Chemother. 2000 Nov;44(11):2932-8.

28.

Pathophysiologic basis of sepsis: considerations for future strategies of intervention.

Glauser MP.

Crit Care Med. 2000 Sep;28(9 Suppl):S4-8. Review.

PMID:
11007189
29.

Deregulation of the arginine deiminase (arc) operon in penicillin-tolerant mutants of Streptococcus gordonii.

Caldelari I, Loeliger B, Langen H, Glauser MP, Moreillon P.

Antimicrob Agents Chemother. 2000 Oct;44(10):2802-10.

30.

Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans.

Marchetti O, Moreillon P, Glauser MP, Bille J, Sanglard D.

Antimicrob Agents Chemother. 2000 Sep;44(9):2373-81.

32.

Neutropenia: clinical implications and modulation.

Glauser MP.

Intensive Care Med. 2000;26 Suppl 1:S103-10. Review. No abstract available.

PMID:
10786966
33.

Protection from septic shock by neutralization of macrophage migration inhibitory factor.

Calandra T, Echtenacher B, Roy DL, Pugin J, Metz CN, Hültner L, Heumann D, Männel D, Bucala R, Glauser MP.

Nat Med. 2000 Feb;6(2):164-70.

PMID:
10655104
34.

Efficacy of levofloxacin in the treatment of experimental endocarditis caused by viridans group streptococci.

Entenza JM, Caldelari I, Glauser MP, Moreillon P.

J Antimicrob Chemother. 1999 Dec;44(6):775-86.

PMID:
10590278
35.

Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study.

Périard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond MJ, Marcovina SM, Glauser MP, Nicod P, Darioli R, Mooser V.

Circulation. 1999 Aug 17;100(7):700-5.

PMID:
10449690
36.

Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients.

Eggimann P, Francioli P, Bille J, Schneider R, Wu MM, Chapuis G, Chiolero R, Pannatier A, Schilling J, Geroulanos S, Glauser MP, Calandra T.

Crit Care Med. 1999 Jun;27(6):1066-72.

PMID:
10397206
37.
38.

Digestion of Streptococcus pneumoniae cell walls with its major peptidoglycan hydrolase releases branched stem peptides carrying proinflammatory activity.

Majcherczyk PA, Langen H, Heumann D, Fountoulakis M, Glauser MP, Moreillon P.

J Biol Chem. 1999 Apr 30;274(18):12537-43.

39.

Molecular basis of host-pathogen interaction in septic shock.

Heumann D, Glauser MP, Calandra T.

Curr Opin Microbiol. 1998 Feb;1(1):49-55. Review.

PMID:
10066457
40.

Changes in renal function associated with indinavir.

Boubaker K, Sudre P, Bally F, Vogel G, Meuwly JY, Glauser MP, Telenti A.

AIDS. 1998 Dec 24;12(18):F249-54.

PMID:
9875572
41.

Efficacy of trovafloxacin in treatment of experimental staphylococcal or streptococcal endocarditis.

Entenza JM, Vouillamoz J, Glauser MP, Moreillon P.

Antimicrob Agents Chemother. 1999 Jan;43(1):77-84.

42.

Dual microsporidial infection due to Vittaforma corneae and Encephalitozoon hellem in a patient with AIDS.

Deplazes P, Mathis A, van Saanen M, Iten A, Keller R, Tanner I, Glauser MP, Weber R, Canning EU.

Clin Infect Dis. 1998 Dec;27(6):1521-4.

43.

Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis.

Jaccard C, Troillet N, Harbarth S, Zanetti G, Aymon D, Schneider R, Chiolero R, Ricou B, Romand J, Huber O, Ambrosetti P, Praz G, Lew D, Bille J, Glauser MP, Cometta A.

Antimicrob Agents Chemother. 1998 Nov;42(11):2966-72. Erratum in: Antimicrob Agents Chemother 1999 Mar;43(3):726.

44.

Nitric oxide production in experimental gram-negative infection: studies with cytokine receptor-deficient mice.

Le Roy D, Heumann D, Glauser MP, Mauël J, Smith J, Betz Corradin S.

Shock. 1998 Jul;10(1):37-42.

PMID:
9688089
45.

Y-688, a new quinolone active against quinolone-resistant Staphylococcus aureus: lack of in vivo efficacy in experimental endocarditis.

Entenza JM, Marchetti O, Glauser MP, Moreillon P.

Antimicrob Agents Chemother. 1998 Aug;42(8):1889-94.

46.

Limited CD4+ T-cell renewal in early HIV-1 infection: effect of highly active antiretroviral therapy.

Fleury S, de Boer RJ, Rizzardi GP, Wolthers KC, Otto SA, Welbon CC, Graziosi C, Knabenhans C, Soudeyns H, Bart PA, Gallant S, Corpataux JM, Gillet M, Meylan P, Schnyder P, Meuwly JY, Spreen W, Glauser MP, Miedema F, Pantaleo G.

Nat Med. 1998 Jul;4(7):794-801.

PMID:
9662370
47.

The pathogenic role of LBP in gram-negative sepsis and septic shock.

Heumann D, Lengacher S, Le Roy D, Jongeneel CV, Glauser MP.

Prog Clin Biol Res. 1998;397:379-86. Review. No abstract available.

PMID:
9575578
48.
49.

Genetic polymorphism of CCR5 gene and HIV disease: the heterozygous (CCR5/delta ccr5) genotype is neither essential nor sufficient for protection against disease progression. Swiss HIV Cohort.

Morawetz RA, Rizzardi GP, Glauser D, Rutschmann O, Hirschel B, Perrin L, Opravil M, Flepp M, von Overbeck J, Glauser MP, Ghezzi S, Vicenzi E, Poli G, Lazzarin A, Pantaleo G.

Eur J Immunol. 1997 Dec;27(12):3223-7.

PMID:
9464809
50.

Cytokines in severe infections: from pathophysiology to clinical applications.

Glauser MP.

Eur Cytokine Netw. 1997 Sep;8(3):317-8. No abstract available.

Supplemental Content

Loading ...
Support Center